tiprankstipranks
Trending News
More News >

Carisma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor downgraded Carisma Therapeutics (CARM) to Neutral from Buy without a price target after the company said it would be discontinuing development of its lead program, CT-0525. The firm awaits more strategic updates and clinical data before becoming more positive on the shares.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1